Clinical trial
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients…
NCT00313781 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00313781 |
|---|---|
| Title | Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) |
| Official title | A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of CP-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | CP-751, 871, docetaxel, prednisone |
| Enrollment | 204 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Apr 12, 2006 |
| Last update posted | Apr 11, 2013 |
| Countries | Canada, Germany, Spain, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: